Phase 1 Mesothelioma Trial, Recruiting NCT06452160 Sponsor: BridGene Biosciences Inc. Condition: Mesothelioma
Back to Mesothelioma

Phase 1 Mesothelioma Trial, Recruiting

NCT06452160
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have signed a consent form agreeing to take part in the study
  • You are male or female and are 18 years old or older
  • Your doctor expects you to live for at least 12 weeks
  • You are generally able to carry out daily activities with little or no difficulty (this is measured using a standard scale called ECOG — confirm with trial site if unsure)
  • (For the first part of the trial — dose escalation): You have been confirmed by lab testing to have advanced or spread mesothelioma, epithelioid hemangioendothelioma (EHE), or another advanced solid tumour, and your cancer has worsened after standard treatments, you could not tolerate those treatments, or standard treatments are not available or refused
  • (For the second part of the trial — dose expansion): You have confirmed advanced or spread mesothelioma, EHE, or another advanced solid tumour with specific changes in a biological pathway called the "Hippo signalling pathway," and your cancer has worsened after standard treatments, you could not tolerate them, or they are not available or refused
  • You have at least one tumour that can be measured on a scan

Who may not be able to join:

  • You have previously used or are currently using a specific type of drug called a TEAD inhibitor
  • You have not waited long enough after finishing your previous cancer treatments before joining (the required waiting period is set out in the trial rules — confirm with trial site)
  • You have a severe or unstable serious illness, or you have cancer that has spread to the brain and is causing symptoms or is unstable
  • You have significant heart or blood vessel problems as defined by the trial rules (confirm with trial site)
  • You are pregnant or currently breastfeeding
  • You have had an allergic reaction to the study drug (BGC515) or any of its ingredients
  • You are a member of the trial staff, a close relative of a trial staff member, a direct report of the trial doctor, or an employee of the company running the trial
  • You have other serious health conditions, abnormal lab results, or other issues that the trial doctor believes would make it unsafe or unsuitable for you to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 408-498-8127

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
BridGene Biosciences Inc.
Registry
ClinicalTrials.gov
Start date
27 June 2024
Est. completion
1 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of adverse events (AEs) and serious adverse events (SAEs).; Dose-limiting toxicities (DLTs); Objective response rate (ORR); Progress-free survival(PFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov